X4 Pharmaceuticals
XFOR
56 hedge funds and large institutions have $28.7M invested in X4 Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 6 closing their positions.
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
8% more funds holding
Funds holding: 52 → 56 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.15% less ownership
Funds ownership: 2.08% → 1.94% (-0.15%)
15% less call options, than puts
Call options by funds: $748K | Put options by funds: $878K
19% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 16
29% less capital invested
Capital invested by funds: $40.2M → $28.7M (-$11.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$385K |
| 2 |
Bank of New York Mellon
New York
|
+$269K |
| 3 |
TLP
Tri Locum Partners
New York
|
+$265K |
| 4 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$254K |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
+$133K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.71M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$892K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$535K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$187K |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$173K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
UBS Group
Zurich,
Switzerland
| $2K | +$1.15K | +20 | +91% |
|
|
CSS
52
Cubist Systematic Strategies
Stamford,
Connecticut
| $2K | +$2.69K | +47 | New |
|
53
Rockefeller Capital Management
New York
| $1K | – | – | – |
|
54
Federated Hermes
Pittsburgh,
Pennsylvania
| $1K | +$287 | +5 | New |
|
55
BNP Paribas Financial Markets
Paris,
France
| $280 | -$229 | -4 | -44% |
|
56
Acadian Asset Management
Boston,
Massachusetts
| – | -$130K | -1,909 | Closed |
|
57
Fidelity Investments
Boston,
Massachusetts
| – | -$121K | -1,768 | Closed |
|
58
Goldman Sachs
New York
| – | -$48K | -698 | Closed |
|
59
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$29K | -426 | Closed |
|
|
EGM
60
Engineers Gate Manager
New York
| – | -$27K | -396 | Closed |
|
61
Wells Fargo
San Francisco,
California
| – | +$57 | +1 | +25% |
|
XFOR Hedge Fund Activity: Q1 2022 in Review
56 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q1 2022, worth a combined $28.7M — down 29% from $40.2M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new XFOR positions and 6 closed out — a net gain of 4 holders — while 13 added to existing stakes and 16 trimmed.
The largest buyer was Millennium Management, adding an estimated $385K. The largest seller was Ikarian Capital, cutting an estimated $1.71M.
- 56 institutional investors held X4 Pharmaceuticals (XFOR) as of Q1 2022, up from 52 in Q4 2021.
- Funds reported $28.7M of X4 Pharmaceuticals stock for Q1 2022, down 29% quarter-over-quarter.
- 10 funds opened new X4 Pharmaceuticals positions in Q1 2022 and 6 closed out, a net change of +4 holders.
- The largest X4 Pharmaceuticals buyer in Q1 2022 was Millennium Management, an estimated $385K added.
- The largest X4 Pharmaceuticals seller in Q1 2022 was Ikarian Capital, an estimated $1.71M sold.
Based on aggregated 13F filings for Q1 2022.